Edward Elliot Graves

Dr. Edward Elliot Graves

Radiation Oncology, Stanford University, Stanford, California, USA
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2020 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
JCJacqueline A. Carozza
Jacqueline A. Carozza
VBVolker Böhnert
Volker Böhnert
KNKhanh C. Nguyen
Khanh C. Nguyen
GSGemini Skariah
Gemini Skariah
KSKelsey E. Shaw
Kelsey E. Shaw
LLLingyin Li
Lingyin Li

1 October 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
DSDanielle A. Simmons
Danielle A. Simmons
FLFrederick M. Lartey
Frederick M. Lartey
ESEmil Schüler
Emil Schüler
MRMarjan Rafat
Marjan Rafat
GKGregory King
Gregory King
BLBilly W Loo
Billy W Loo

10 August 2004 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VNVasilis Ntziachristos
Vasilis Ntziachristos
ESEyk A. Schellenberger
Eyk A. Schellenberger
JRJorge Ripoll
Jorge Ripoll
DYDoreen Yessayan
Doreen Yessayan
Edward Elliot GravesEdward Elliot Graves
Edward Elliot Graves
RWRalph Weissleder
Ralph Weissleder
In vivo imaging of treatment responses at the molecular level could have a significant impact on the speed of drug discovery and ultimately lead to personalized medicine. Strong interest has been shown in developing quantitative fluorescence-based technologies with good molecular specificity and sensitivity for noninvasive 3D imaging through tissues and whole animals. We show herein that tumor response to chemotherapy can be accurately resolved by fluorescence molecular tomography (FMT) with a phosphatidylserine-sensing fluorescent probe based on modified annexins. We observed at least a 10-fold increase of fluorochrome concentration in cyclophosphamide-sensitive tumors and a 7-fold increase of resistant tumors compared with control studies. FMT is an optical imaging technique developed to overcome limitations of commonly used planar illumination methods and demonstrates higher quantification accuracy validated by histology. It is further shown that a 3-fold variation in background absorption heterogeneity may yield 100% errors in planar imaging but only 20% error in FMT, thus confirming tomographic imaging as a preferred tool for quantitative investigations of fluorescent probes in tissues. Tomographic approaches are found essential for small-animal optical imaging and are potentially well suited for clinical drug development and monitoring.

21 November 2022 in Nature Cancer
Verified
Journal Article
Open access
PDF file
YNYoko Nishiga
Yoko Nishiga
ADAlexandros P. Drainas
Alexandros P. Drainas
MBMaya Baron
Maya Baron
DBDebadrita Bhattacharya
Debadrita Bhattacharya
ABAmira A. Barkal
Amira A. Barkal
JSJulien Sage
Julien Sage
Radiation therapy is a mainstay of cancer treatment but does not always lead to complete tumor regression. Here we combine radiotherapy with blockade of the ‘don’t-eat-me’ cell-surface molecule CD47 in small cell lung cancer (SCLC), a highly metastatic form of lung cancer. CD47 blockade potently enhances the local antitumor effects of radiotherapy in preclinical models of SCLC. Notably, CD47 blockade also stimulates off-target ‘abscopal’ effects inhibiting non-irradiated SCLC tumors in mice receiving radiation. These abscopal effects are independent of T cells but require macrophages that migrate into non-irradiated tumor sites in response to inflammatory signals produced by radiation and are locally activated by CD47 blockade to phagocytose cancer cells. Similar abscopal antitumor effects were observed in other cancer models treated with radiation and CD47 blockade. The systemic activation of antitumor macrophages following radiotherapy and CD47 blockade may be particularly important in patients with cancer who suffer from metastatic disease.

27 August 2020 in Radiation Research
Verified
Journal Article
Open access
PDF file
LSLuis A. Soto
Luis A. Soto
KCKerriann M. Casey
Kerriann M. Casey
JWJinghui Wang
Jinghui Wang
ABAlexandra Blaney
Alexandra Blaney
RMRakesh Manjappa
Rakesh Manjappa
BLBilly W Loo
Billy W Loo
Radiation therapy, along with surgery and chemotherapy, is one of the main treatments for cancer. While radiotherapy is highly effective in the treatment of localized tumors, its main limitation is its toxicity to normal tissue. Previous preclinical studies have reported that ultra-high dose-rate (FLASH) irradiation results in reduced toxicity to normal tissues while controlling tumor growth to a similar extent relative to conventional-dose-rate (CONV) irradiation. To our knowledge this is the first report of a dose-response study in mice comparing the effect of FLASH irradiation vs. CONV irradiation on skin toxicity. We found that FLASH irradiation results in both a lower incidence and lower severity of skin ulceration than CONV irradiation 8 weeks after single-fraction hemithoracic irradiation at high doses (30 and 40 Gy). Survival was also higher after FLASH hemithoracic irradiation (median survival >180 days at doses of 30 and 40 Gy) compared to CONV irradiation (median survival 100 and 52 days at 30 and 40 Gy, respectively). No ulceration was observed at doses 20 Gy or below in either FLASH or CONV. These results suggest a shifting of the dose-response curve for radiation-induced skin ulceration to the right for FLASH, compared to CONV irradiation, suggesting the potential for an enhanced therapeutic index for radiation therapy of cancer.

1 June 2004 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
Edward Elliot GravesEdward Elliot Graves
Edward Elliot Graves
RWR. Weissleder
R. Weissleder
VNV. Ntziachristos
V. Ntziachristos
In vivo imaging of molecular events in small animals has great potential to impact basic science and drug development. For this reason, several imaging technologies have been adapted to small animal research, including X-ray, magnetic resonance, and radioisotope imaging. Despite this plethora of visualization techniques, fluorescence imaging is emerging as an important alternative because of its operational simplicity, safety, and cost-effectiveness. Fluorescence imaging has recently become particularly interesting because of advances in fluorescent probe technology, including targeted fluorochromes as well as fluorescent “switches” sensitive to specific biochemical events. While past biological investigations using fluorescence have focused on microscopic examination of ex vivo, in vitro, or intravital specimens, techniques for macroscopic fluorescence imaging are now emerging for in vivo molecular imaging applications. This review illuminates fluorescence imaging technologies that hold promise for small animal imaging. In particular we focus on planar illumination techniques, also known as Fluorescence Reflectance Imaging (FRI), and discuss its performance and current use. We then discuss fluorescence molecular tomography (FMT), an evolving technique for quantitative three-dimensional imaging of fluorescence in vivo. This technique offers the promise of non-invasively quantifying and visualizing specific molecular activity in living subjects in three dimensions.